vs
Side-by-side financial comparison of Evolus, Inc. (EOLS) and HARROW, INC. (HROW). Click either name above to swap in a different company.
Evolus, Inc. is the larger business by last-quarter revenue ($90.3M vs $89.1M, roughly 1.0× HARROW, INC.). HARROW, INC. runs the higher net margin — 7.4% vs 0.1%, a 7.3% gap on every dollar of revenue. On growth, HARROW, INC. posted the faster year-over-year revenue change (33.3% vs 14.4%). Evolus, Inc. produced more free cash flow last quarter ($11.3M vs $8.1M). Over the past eight quarters, HARROW, INC.'s revenue compounded faster (60.5% CAGR vs 23.4%).
Evolus, Inc. is a medical aesthetics company focused on developing and commercializing non-surgical cosmetic treatment solutions. Its flagship product is a prescription neuromodulator designed to reduce moderate to severe glabellar frown lines, serving licensed aesthetic healthcare providers and consumers across North America, Europe, and key Asia-Pacific regional markets.
Harrow Health, Inc., formerly known as Imprimis Pharmaceuticals, is a publicly traded pharmaceutical company based in Nashville, Tennessee.
EOLS vs HROW — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $90.3M | $89.1M |
| Net Profit | $130.0K | $6.6M |
| Gross Margin | 65.7% | 79.3% |
| Operating Margin | 4.7% | 17.5% |
| Net Margin | 0.1% | 7.4% |
| Revenue YoY | 14.4% | 33.3% |
| Net Profit YoY | 101.9% | -2.2% |
| EPS (diluted) | $0.01 | $0.20 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $90.3M | $89.1M | ||
| Q3 25 | $69.0M | $71.6M | ||
| Q2 25 | $69.4M | $63.7M | ||
| Q1 25 | $68.5M | $47.8M | ||
| Q4 24 | $78.9M | $66.8M | ||
| Q3 24 | $61.1M | $49.3M | ||
| Q2 24 | $66.9M | $48.9M | ||
| Q1 24 | $59.3M | $34.6M |
| Q4 25 | $130.0K | $6.6M | ||
| Q3 25 | $-15.7M | $1.0M | ||
| Q2 25 | $-17.1M | $5.0M | ||
| Q1 25 | $-18.9M | $-17.8M | ||
| Q4 24 | $-6.8M | $6.8M | ||
| Q3 24 | $-19.2M | $-4.2M | ||
| Q2 24 | $-11.3M | $-6.5M | ||
| Q1 24 | $-13.1M | $-13.6M |
| Q4 25 | 65.7% | 79.3% | ||
| Q3 25 | 66.5% | 75.3% | ||
| Q2 25 | 65.3% | 74.5% | ||
| Q1 25 | 68.1% | 67.5% | ||
| Q4 24 | 66.7% | 78.8% | ||
| Q3 24 | 68.9% | 75.6% | ||
| Q2 24 | 70.3% | 74.4% | ||
| Q1 24 | 68.3% | 69.5% |
| Q4 25 | 4.7% | 17.5% | ||
| Q3 25 | -16.7% | 20.6% | ||
| Q2 25 | -14.7% | 17.9% | ||
| Q1 25 | -22.1% | -23.5% | ||
| Q4 24 | -2.9% | 19.3% | ||
| Q3 24 | -25.3% | 2.7% | ||
| Q2 24 | -11.5% | 3.1% | ||
| Q1 24 | -15.0% | -20.0% |
| Q4 25 | 0.1% | 7.4% | ||
| Q3 25 | -22.8% | 1.4% | ||
| Q2 25 | -24.7% | 7.8% | ||
| Q1 25 | -27.6% | -37.2% | ||
| Q4 24 | -8.6% | 10.1% | ||
| Q3 24 | -31.4% | -8.6% | ||
| Q2 24 | -17.0% | -13.2% | ||
| Q1 24 | -22.1% | -39.2% |
| Q4 25 | $0.01 | $0.20 | ||
| Q3 25 | $-0.24 | $0.03 | ||
| Q2 25 | $-0.27 | $0.13 | ||
| Q1 25 | $-0.30 | $-0.50 | ||
| Q4 24 | $-0.11 | $0.19 | ||
| Q3 24 | $-0.30 | $-0.12 | ||
| Q2 24 | $-0.18 | $-0.18 | ||
| Q1 24 | $-0.22 | $-0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $53.8M | $72.9M |
| Total DebtLower is stronger | $146.1M | $250.0M |
| Stockholders' EquityBook value | $-23.1M | $52.4M |
| Total Assets | $225.9M | $399.5M |
| Debt / EquityLower = less leverage | — | 4.77× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $53.8M | $72.9M | ||
| Q3 25 | $43.5M | $74.3M | ||
| Q2 25 | $61.7M | $53.0M | ||
| Q1 25 | $67.9M | $66.7M | ||
| Q4 24 | $87.0M | $47.2M | ||
| Q3 24 | $85.0M | $72.6M | ||
| Q2 24 | $93.7M | $71.0M | ||
| Q1 24 | $97.0M | $76.0M |
| Q4 25 | $146.1M | $250.0M | ||
| Q3 25 | — | $347.2M | ||
| Q2 25 | — | $250.6M | ||
| Q1 25 | $121.8M | $256.9M | ||
| Q4 24 | $121.5M | $262.7M | ||
| Q3 24 | $121.2M | $230.7M | ||
| Q2 24 | $120.9M | $236.3M | ||
| Q1 24 | $120.6M | $243.4M |
| Q4 25 | $-23.1M | $52.4M | ||
| Q3 25 | $-28.8M | $47.0M | ||
| Q2 25 | $-18.7M | $49.7M | ||
| Q1 25 | $-6.6M | $56.5M | ||
| Q4 24 | $5.5M | $69.7M | ||
| Q3 24 | $5.9M | $58.0M | ||
| Q2 24 | $19.3M | $58.5M | ||
| Q1 24 | $18.4M | $60.6M |
| Q4 25 | $225.9M | $399.5M | ||
| Q3 25 | $219.0M | $363.1M | ||
| Q2 25 | $228.8M | $345.0M | ||
| Q1 25 | $213.4M | $364.2M | ||
| Q4 24 | $232.6M | $389.0M | ||
| Q3 24 | $229.6M | $351.5M | ||
| Q2 24 | $233.8M | $306.6M | ||
| Q1 24 | $226.2M | $295.5M |
| Q4 25 | — | 4.77× | ||
| Q3 25 | — | 7.39× | ||
| Q2 25 | — | 5.05× | ||
| Q1 25 | — | 4.55× | ||
| Q4 24 | 22.00× | 3.77× | ||
| Q3 24 | 20.58× | 3.98× | ||
| Q2 24 | 6.26× | 4.04× | ||
| Q1 24 | 6.54× | 4.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $12.8M | $8.4M |
| Free Cash FlowOCF − Capex | $11.3M | $8.1M |
| FCF MarginFCF / Revenue | 12.6% | 9.1% |
| Capex IntensityCapex / Revenue | 1.6% | 0.4% |
| Cash ConversionOCF / Net Profit | 98.67× | 1.27× |
| TTM Free Cash FlowTrailing 4 quarters | $-45.7M | $43.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $12.8M | $8.4M | ||
| Q3 25 | $-14.7M | $16.6M | ||
| Q2 25 | $-24.8M | $-803.0K | ||
| Q1 25 | $-15.6M | $19.7M | ||
| Q4 24 | $4.8M | $-17.8M | ||
| Q3 24 | $-5.7M | $3.0M | ||
| Q2 24 | $-6.5M | $-2.7M | ||
| Q1 24 | $-10.6M | $-4.6M |
| Q4 25 | $11.3M | $8.1M | ||
| Q3 25 | $-15.6M | $16.4M | ||
| Q2 25 | $-25.5M | $-969.0K | ||
| Q1 25 | $-16.0M | $19.5M | ||
| Q4 24 | $4.4M | $-18.3M | ||
| Q3 24 | $-6.0M | $2.3M | ||
| Q2 24 | $-6.9M | $-3.1M | ||
| Q1 24 | $-10.9M | $-4.7M |
| Q4 25 | 12.6% | 9.1% | ||
| Q3 25 | -22.7% | 22.9% | ||
| Q2 25 | -36.7% | -1.5% | ||
| Q1 25 | -23.3% | 40.8% | ||
| Q4 24 | 5.5% | -27.4% | ||
| Q3 24 | -9.9% | 4.8% | ||
| Q2 24 | -10.4% | -6.3% | ||
| Q1 24 | -18.3% | -13.6% |
| Q4 25 | 1.6% | 0.4% | ||
| Q3 25 | 1.4% | 0.3% | ||
| Q2 25 | 1.0% | 0.3% | ||
| Q1 25 | 0.5% | 0.4% | ||
| Q4 24 | 0.6% | 0.8% | ||
| Q3 24 | 0.5% | 1.2% | ||
| Q2 24 | 0.7% | 0.7% | ||
| Q1 24 | 0.4% | 0.3% |
| Q4 25 | 98.67× | 1.27× | ||
| Q3 25 | — | 16.26× | ||
| Q2 25 | — | -0.16× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -2.62× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
